/
Oncology
Diffuse Large B-Cell Lymphoma(dlbcl)
20
Pipeline Programs↗
12
Active Trials↗
11
Companies Involved↗
Diffuse Large B-cell Lymphoma(DLBCL) is an emerging landscape with 20 programs across 11 companies. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Phase 1
No programs
Phase 215
Approved
No programs
Analysis
Modality Breakdown
67%
Small molecule
12 of 18 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 90% of 20 pipeline programs.
Analysis
Trial Status
12
clinical trials
Recruiting7 · 58%
Not yet recruiting5 · 42%
Clinical Trials
Trial Activity
12 trials
An Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07599423·96 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)